Aglatimagene besadenovec
Candel Therapeutics · CAN-2409
FollowEvery change as it happens, and a Monday email
Trials
5 active
13 in total
Targets
—
None known yet
What this is
- How it works
- Gene therapy: adenovirus carrying a herpes virus enzyme gene, given with a prodrug
- How it’s given
- “Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows: 1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation. 2. The second injection will be 0-3 days before initiation…”In the company’s words, NCT01436968 on ClinicalTrials.gov
- Tested for
- Prostate Cancer (2 trials), Non-squamous, Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- Main trialPhase 3
- “The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity and lower than expected recurrence rates in previous clinical trials. The hypothesis is that ProstAtak can lead to improvement in the clinical…”In the company’s words, NCT01436968 on ClinicalTrials.gov
- Other names
- CAN-2409 · AdV-tk
Other drugs for Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up2
- Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 22 Oct 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Aug 2024 | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | |
| Phase 3Recruiting | 22 Oct 2031 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) | |
| Phase 2Active, not recruiting | Nov 2024 | Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | |
| Phase 2Active, not recruiting | 31 Dec 2024 | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | |
| Phase 2Recruiting | Feb 2027 | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | |
| Phase 2Completed | Dec 2015 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | |
| Phase 2Unknown | Dec 2025 | Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma | |
| Phase 1Completed | Jan 2010 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | |
| Phase 1Completed | May 2013 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) | |
| Phase 1Completed | Dec 2015 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | |
| Phase 1Completed | Dec 2015 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion | |
| Phase 1Completed | 1 Dec 2021 | Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer | |
| Phase 1Completed | 30 Jun 2023 | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026